Analyst David Nierengarten of Wedbush reiterated a Buy rating on Inozyme Pharma (INZY – Research Report), retaining the price target of $7.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Nierengarten’s rating is based on promising interim results from Inozyme Pharma’s pivotal ENERGY-3 study, which demonstrated significant improvements in serum phosphate levels in patients treated with INZ-701. The data showed that INZ-701 effectively addresses hypophosphatemia and its related skeletal complications in pediatric patients with ENPP1 deficiency. Furthermore, the safety profile of INZ-701 appears favorable, with no treatment discontinuations or significant safety concerns identified by the DSMB.
Additionally, the immunogenicity findings were encouraging, as most patients exhibited no or low titer ADA responses, suggesting minimal impact on the drug’s efficacy. The company’s financial position is also stable, with sufficient cash reserves to support operations into the first quarter of 2026. Given the potential for INZ-701 to become a first-in-class therapy for ENPP1 deficiency by 2026, Nierengarten views Inozyme Pharma as an attractive investment opportunity for patient investors.
In another report released today, Raymond James also maintained a Buy rating on the stock with a $12.00 price target.
INZY’s price has also changed dramatically for the past six months – from $3.430 to $1.350, which is a -60.64% drop .